SEZóNA: 1
OBSAH
When drugmaker Valeant began to grow at dizzying speeds, investors were thrilled. But a handful of skeptics realized something was very wrong.
- Matt TaibbiSelf - Correspondent, Rolling Stone
- Fisher StevensSelf - Interviewer
- Alex GibneySelf - Presenter
- Fahmi QuadirSelf - Short Seller, Safkhet Capital
- Scott TuckerSelf - CEO of AMG Services
- Anabel HernándezSelf - Investigative Journalist
- Simon TrépanierSelf - Executive Director, Federation of Maple Syr
- Rachel AvivSelf - Reporter, The New Yorker